Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623966 | 0.91 | SHMT1 (0.33) | CNR2KDM4EANO1LIPG | |
| SCHEMBL13623975 | 0.89 | LIPG (0.33) | CNR2ANO1LIPGNTRK1 | |
| SCHEMBL4272664 | 0.87 | ANO1 (0.33) | CNR2KDM4EANO1LIPGLMNA | |
| SCHEMBL12378423 | 0.87 | CNR2 (0.46) | CNR2ANO1CNR1LIPGKMT2A | |
| SCHEMBL3992850 | 0.87 | GPR52 (0.34) | KDM4ELIPGLMNAKMT2ANTRK1 | |
| SCHEMBL12378442 | 0.86 | CDK9 (0.37) | KDM4ELIPGLMNANTRK1 | |
| SCHEMBL13624116 | 0.85 | LIPG (0.31) | LIPG | |
| SCHEMBL13623970 | 0.85 | PTGER4 (0.32) | LIPG | |
| SCHEMBL13623968 | 0.85 | GAA (0.39) | LIPGKMT2ANTRK1 | |
| SCHEMBL13624008 | 0.85 | CNR2 (0.38) | CNR2CNR1LIPGNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009067541-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067541-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | TYMP, DNTT, PAICS | CNR2 4717/4885KDM4E 1971/4885ANO1 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.